CSR Synopses following approval of a new medicine or a new indication for an approved medicine in the US or EU. We are making CSR synopses available to supplement the public information available to patients and healthcare providers about the results of our clinical trials and the evidence used to approve a new medicine or a new indication.
Clarithromycin: Biaxin, Clacee, Klaricid, Klacid
|M02-524||Sinusitis||CSR.ORG||A Phase IIIB/IV Comparative Study of the Safety and Efficacy of Clarithromycin Extended-release Tablets vs. Amoxicillin-clavulan…|
|M02-472||Bronchitis||CSR.ORG||A Phase III Comparative Efficacy Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin…|
|FRAN-02-002||Acute bacterial exacerbations of chronic bronchitis||CSR.ORG||Efficacy and safety of extended-release clarithromycin (5-day short-course) vs telithromycin, in acute bacterial exacerbation of chronic bronchitis Perronne C, Drugeon H, Zuck P, et al. Efficacy and safety of extended-release clarithromycin (5-day short-course) vs telithromycin, in acute bacterial exacerbation of chronic bronchitis. Available online at http://france.elsevier.com/direct/MEDMAL...|
No results found